← Eichor
Condition: Pembrolizumab Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Pembrolizumab

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Uppe
Phase 2 · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT05775471Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
Phase 1 · 2 location(s) · University of Chicago · NCT04295863Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
Phase 2 · 6 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06745882Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06389422Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia
Phase 2 · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT04712851Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combina
Phase 2/Phase 3 · 770 location(s) · Mirati Therapeutics Inc. · NCT04613596Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Hist
Phase 2 · 4 location(s) · Emory University · NCT05756569Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected
Phase 1/Phase 2 · 6 location(s) · Everest Medicines (Beijing) Co., Ltd. · NCT07095868Sacituzumab Govitecan Plus EV in Metastatic UC
Phase 1/Phase 2 · 1 location(s) · Dana-Farber Cancer Institute · NCT04724018Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresecta
Phase 2 · 1 location(s) · Philogen S.p.A. · NCT06284590Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic On
Phase 2 · 2 location(s) · Fudan University · NCT05281003Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)
Phase 1/Phase 2 · 4 location(s) · Amsterdam UMC, location VUmc · NCT06384560A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Ca
Phase 3 · 205 location(s) · Merus B.V. · NCT06525220Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
Phase 2 · 1 location(s) · Mayo Clinic · NCT07087860Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unr
Phase 1 · 1 location(s) · Aaron Wolfson · NCT05603910A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Phase 1/Phase 2 · 25 location(s) · Merck Sharp & Dohme LLC · NCT07286149High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metast
Phase 2 · 1 location(s) · Emory University · NCT06492759Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Phase 2 · 18 location(s) · Canadian Cancer Trials Group · NCT05180097A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06246968BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Phase 1/Phase 2 · 25 location(s) · BioInvent International AB · NCT04752826A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
Phase 3 · 1 location(s) · Sinocelltech Ltd. · NCT07362459A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT04683679A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With
Phase 1 · 1 location(s) · Providence Health & Services · NCT06719362A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-L
Phase 3 · 403 location(s) · Amgen · NCT05920356Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invas
Phase 3 · 11 location(s) · Astellas Pharma Global Development, Inc. · NCT07566156Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
Phase 2 · 3 location(s) · University of Colorado, Denver · NCT05969496Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
Phase 1 · 14 location(s) · Riboscience, LLC. · NCT05270213A Study of EBC-129 in Advanced Solid Tumours
Phase 1 · 5 location(s) · EDDC (Experimental Drug Development Centre), A*STAR Research · NCT05701527Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
Phase 2 · 20 location(s) · UNICANCER · NCT05973864Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer
Phase 2 · 14 location(s) · Yukinori Ozaki · NCT06976944
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.